Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Clinical treatment programs	$ 36	$ 49	$ 78	$ 121
Total revenues	36	49	78	121
Costs and expenses:
Production/cost of goods sold	635	208	826	488
Research and development	2,318	1,736	4,654	3,401
General and administrative	1,817	1,738	3,894	3,612
Total costs and expenses	4,770	3,682	9,374	7,501
Operating loss	(4,734)	(3,633)	(9,296)	(7,380)
Interest expense	(5)	(1)	(10)	(12)
Interest and other income	354	247	535	520
Funds received from sale of income tax net operating losses	0	0	686	1,328
Redeemable warrants valuation adjustment	102	387	191	236
Net loss	(4,283)	(3,000)	(7,894)	(5,308)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	(1,005)	187	(960)	584
Realized loss on securities	(77)	(21)	(87)	(37)
Less: Premium amortization	1	48	2	108
Net comprehensive loss	$ (5,364)	$ (2,786)	$ (8,939)	$ (4,653)
Basic and diluted loss per share (usd per share)	$ (0.03)	$ (0.02)	$ (0.05)	$ (0.04)
Weighted average shares outstanding, basic and diluted (shares)	167,202,512	135,974,216	167,005,714	135,880,841